Low-dose oral sirolimus and the risk of menstrual-cycle disturbances and ovarian cysts: analysis of the randomized controlled SUISSE ADPKD trial.

Low-dose oral sirolimus and the risk of menstrual-cycle disturbances and ovarian cysts: analysis of the randomized controlled SUISSE ADPKD trial.

Sirolimus has been approved for clinical use in non proliferative and proliferative disorders. It inhibits the mammalian target of rapamycin (mTOR) signaling pathway which is also known to regulate ovarian morphology and function. Preliminary observational data suggest the potential for ovarian toxi...

Full description

Bibliographic Details
Main Authors: Matthias Braun, James Young, Cäcilia S Reiner, Diane Poster, Fabienne Krauer, Andreas D Kistler, Paulus Kristanto, Xueqi Wang, Yang Liu, Johannes Loffing, Gustav Andreisek, Arnold von Eckardstein, Oliver Senn, Rudolf P Wüthrich, Andreas L Serra
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3468602?pdf=render

Internet

http://europepmc.org/articles/PMC3468602?pdf=render

Similar Items